Monday, December 05, 2016
 
 
Video: Page (1) of 1 - 10/11/12 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Intercept Pharmaceuticals Announces IPO Pricing

By DMO Affiliate
Intercept Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from Intercept.
Intercept Pharmaceuticals Announces IPO Pricing




Page: 1


null
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines